Emergent Biosolutions (NYSE:EBS) Earns Underweight Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Emergent Biosolutions (NYSE:EBS) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued an underweight rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the company. HC Wainwright dropped their price target on Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Emergent Biosolutions in a report on Friday, August 7th. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Emergent Biosolutions has an average rating of “Hold” and a consensus price target of $10.00.

Emergent Biosolutions Price Performance

Shares of EBS opened at $5.07 on Friday. Emergent Biosolutions has a 1-year low of $4.36 and a 1-year high of $14.06. The stock has a market cap of $259.94 million, a PE ratio of -1.43 and a beta of 2.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The firm has a fifty day moving average price of $7.11 and a 200 day moving average price of $8.25.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The company had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. As a group, sell-side analysts anticipate that Emergent Biosolutions will post -4.63 EPS for the current year.

Insider Activity

In related news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the transaction, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. The trade was a 1.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $31,000. Public Employees Retirement System of Ohio purchased a new stake in Emergent Biosolutions in the 2nd quarter valued at approximately $36,000. Torren Management LLC acquired a new position in Emergent Biosolutions during the 4th quarter worth approximately $37,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of Emergent Biosolutions during the 4th quarter worth approximately $45,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at approximately $53,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.